

In The Claims:

Please substitute the following claims for the pending claims of the same number.

Claim 3. (Once Amended) A nutritional or dietary supplement composition to safely and effectively prevent stabilize and/or treat visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the formation of cataracts and the progression of age-related macular degeneration comprising:

approximately 7 to 10 times the RDA of vitamin C;
approximately 13 to 18 times the RDA of vitamin E;
approximately 6 to 10 times the RDA of vitamin A in the form of beta-carotene;
approximately 4 to 7 times the RDA of zinc; and
approximately the RDA of copper.

Claim 4. (Once Amended)

A method of safely and effectively

preventing, stabilizing and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising:

B1

administering a daily dosage of not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper.

Claim 5. (Once Amended)

A method of manufacturing a nutritional supplement composition that is safe and effective in preventing, stabilizing and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising:

blending not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper into a suitable dosage form.

**VERSION WITH MARKINGS TO SHOW
CHANGES MADE**

In The Claims:

The above claims have been amended as shown in the claims below of the same number wherein added words are underlined and deleted words are [bracketed].

Claim 3. (Once Amended) A nutritional or dietary supplement composition to safely and effectively prevent, stabilize [, reverse] and/or treat visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the formation of cataracts and the progression of age-related macular degeneration comprising:

- approximately 7 to 10 times the RDA of vitamin C;
- approximately 13 to 18 times the RDA of vitamin E;
- approximately 6 to 10 times the RDA of vitamin A in the form of beta-carotene;
- approximately 4 to 7 times the RDA of zinc; and
- approximately the RDA of copper.

Claim 4. (Once Amended)

A method of safely and effectively preventing, stabilizing[,reversing] and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising:

administering a daily dosage of not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper.

Claim 5. (Once Amended)

A method of manufacturing a nutritional supplement composition that is safe and effective in preventing, stabilizing[, reversing] and/or treating visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration and by reducing the risk of vision loss associated with the development of cataracts and the progression of age-related macular degeneration comprising:

blending not less than approximately 420 mg and not more than approximately 600 mg vitamin C, not less than approximately 400 IU and not more than approximately 540 IU vitamin E, not less than approximately 17.2 mg and not more than approximately 28 mg beta-carotene, not less than approximately 60 mg and not more than approximately 100 mg zinc and not less than approximately 1.6 mg and not more than approximately 2.4 mg copper into a suitable dosage form.